Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 1/20 | 0.44 |
| ▸ | PPARA | Q07869 | 1/20 | 0.44 |
| ▸ | FTO | Q9C0B1 | 2/20 | 0.38 |
| ▸ | HPGD | P15428 | 2/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6277581 | 0.78 | CYP3A4 (0.51) | PPARGPPARAHPGDLMNAALDH1A1 | |
| SCHEMBL3246809 | 0.75 | PPARA (0.46) | PPARAFTO | |
| SCHEMBL7723225 | 0.69 | PTGES (0.35) | PPARGPPARA | |
| SCHEMBL6278672 | 0.67 | PPARG (0.43) | PPARGPPARAHPGDALDH1A1CYP3A4 | |
| SCHEMBL3262766 | 0.65 | ALDH1A1 (0.59) | FTOHPGDHSD17B10ALDH1A1 | |
| SCHEMBL6278799 | 0.65 | PPARA (0.47) | PPARGPPARAHPGDTSHRHSD17B10 | |
| SCHEMBL6281574 | 0.65 | PPARG (0.43) | PPARGPPARA | |
| SCHEMBL6278711 | 0.64 | PPARA (0.42) | PPARGPPARA | |
| SCHEMBL11850892 | 0.64 | FTO (0.40) | FTOLMNATDP1 | |
| SCHEMBL6278638 | 0.63 | PPARG (0.38) | PPARGPPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1539137-B1 | PPAR ALPHA SELECTIVE COMPOUNDS FOR THE TREATMENT OF DYSLIPIDEMIA AND OTHER LIPID DISORDERS | MERCK SHARP & DOHME (US) | 2010-05-26 | — | — | EP | disclosed |
| US-7297715-B2 | PPAR alpha selective compounds for the treatment of dyslipidemia and other lipid disorders | MERCK & CO., INC. (US) | 2007-11-20 | — | — | US | disclosed |
| EP-1539137-A4 | PPAR ALPHA SELECTIVE COMPOUNDS FOR THE TREATMENT OF DYSLIPIDEMIA AND OTHER LIPID DISORDERS | MERCK & CO INC (US) | 2007-11-14 | — | — | EP | disclosed |
| US-20060089404-A1 | Ppar alpha selective compounds for the treatment of dyslipidemia and other lipid disorders | MERCK SHARP & DOHME CORP. | 2006-04-27 | — | — | US | disclosed |
| EP-1539137-A1 | PPAR ALPHA SELECTIVE COMPOUNDS FOR THE TREATMENT OF DYSLIPIDEMIA AND OTHER LIPID DISORDERS | Merck & Co., Inc. (US) | 2005-06-15 | — | — | EP | disclosed |
| WO-2004010992-A1 | PPAR ALPHA SELECTIVE COMPOUNDS FOR THE TREATMENT OF DYSLIPIDEMIA AND OTHER LIPID DISORDERS | MERCK & CO., INC. (US) | 2004-02-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060089404-A1 | Ppar alpha selective compounds for the treatment of dyslipidemia and other lipid disorders | PPARA, PPARG, PPARD | PPARG 2/4885PPARA 1/4885FTO 4751/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.